Trial · NCT01153425
µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
NCT01153425, Phase 4, Completed, University of Pennsylvania; results first posted 2017-08-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis. Trials, record NCT01153425. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01153425
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
- NCT number
- NCT01153425
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 33 participants, actual
- Lead sponsor
- University of Pennsylvania
- Conditions
- Osteoporosis, Osteopenia
- Interventions
- Virtual Bone Biopsy, Teriparatide, Zoledronic Acid
- First posted
- 2010-06-30
- Last updated
- 2017-08-04
- Results first posted
- 2017-08-04
- Limitations and caveats
- Insufficient Power
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Change in Trabecular Surface-to-curve Ratio | Change between baseline and 12 months | Ratio of the volume densities of surface (S) and curve (C)-type voxels, S/C |
| Secondary | Percentage of Change in Bone Volume Fraction (BVF) | Change between baseline and 12 months | Average fractional content of bone expressed in percent |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Change in Trabecular Surface-to-curve Ratio | Change between baseline and 12 months | Mean change in structural and mechanical markers of bone turnover between the two groups. | Percentage of Change | MEAN |
| SECONDARY | Percentage of Change in Bone Volume Fraction (BVF) | Change between baseline and 12 months | Percentage of Change | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Change in Trabecular Surface-to-curve Ratio | Teriparatide (Forteo) | 9.1 | Standard Deviation 2.0 | Percentage of Change | |
| Percentage of Change in Trabecular Surface-to-curve Ratio | Zoledronic Acid (Reclast) | 7.1 | Standard Deviation 2.6 | Percentage of Change | |
| Percentage of Change in Bone Volume Fraction (BVF) | Teriparatide (Forteo) | 1.0 | Standard Deviation 0.8 | Percentage of Change | |
| Percentage of Change in Bone Volume Fraction (BVF) | Zoledronic Acid (Reclast) | 0.6 | Standard Deviation 0.3 | Percentage of Change |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Teriparatide (Forteo) | 16 | |
| Overall Study | STARTED | Zoledronic Acid (Reclast) | 17 | |
| Overall Study | COMPLETED | Teriparatide (Forteo) | 13 | |
| Overall Study | COMPLETED | Zoledronic Acid (Reclast) | 14 | |
| Overall Study | NOT COMPLETED | Teriparatide (Forteo) | 3 | |
| Overall Study | NOT COMPLETED | Zoledronic Acid (Reclast) | 3 |
Source ClinicalTrials.gov
Adverse events28
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Moderate | Gastrointestinal disorders | Teriparatide (Forteo) | 0 | 16 | 0 |
| other | Moderate | Gastrointestinal disorders | Zoledronic Acid (Reclast) | 1 | 17 | 1 |
| other | Moderate | General disorders | Teriparatide (Forteo) | 0 | 16 | 0 |
| other | Moderate | General disorders | Zoledronic Acid (Reclast) | 2 | 17 | 2 |
| other | Moderate | Blood and lymphatic system disorders | Teriparatide (Forteo) | 2 | 16 | 3 |
| other | Moderate | Blood and lymphatic system disorders | Zoledronic Acid (Reclast) | 0 | 17 | 0 |
| other | Moderate | Eye disorders | Teriparatide (Forteo) | 1 | 16 | 1 |
| other | Moderate | Eye disorders | Zoledronic Acid (Reclast) | 0 | 17 | 0 |
| other | Moderate | Skin and subcutaneous tissue disorders | Teriparatide (Forteo) | 1 | 16 | 1 |
| other | Moderate | Skin and subcutaneous tissue disorders | Zoledronic Acid (Reclast) | 0 | 17 | 0 |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Teriparatide (Forteo) | 0 | 16 |
| Total, all-cause mortality | Zoledronic Acid (Reclast) | 0 | 17 |
| Total, other adverse events | Teriparatide (Forteo) | 15 | 16 |
| Total, other adverse events | Zoledronic Acid (Reclast) | 12 | 17 |
| Total, serious adverse events | Teriparatide (Forteo) | 1 | 16 |
| Total, serious adverse events | Zoledronic Acid (Reclast) | 0 | 17 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01AR041443 | NMR imaging and stereologic analysis of trabecular bone | WEHRLI, FELIX W | UNIVERSITY OF PENNSYLVANIA | NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES | 1993 to 2009 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Teriparatide (Forteo) vs Zoledronic Acid (Reclast): deaths from any cause | Trial comparisons |
| Teriparatide (Forteo) vs Zoledronic Acid (Reclast): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01153425
GET https://conductscience.org/api/trials/v1/NCT01153425/events?page=2